A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

This trial is studying a new CAR-T cell therapy targeting a protein called GPRC5D, which is found on the surface of multiple myeloma cells. CAR-T therapy uses the patient's own immune cells, modified in a lab to seek and destroy cancer cells. This is for people whose myeloma has come back or stopped responding to multiple prior treatments. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with multiple myeloma or plasma cell leukemia that has returned or no longer responds to treatment - You have already tried at least 3 prior treatment regimens, including drugs from at least two major myeloma drug classes **You may NOT be eligible if...** - You have active serious infections or uncontrolled disease in another organ - You have previously received anti-GPRC5D treatment - You have significant heart, lung, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.